From the datasets examined, elevated KPNA2 mRNA levels had no significant overall prognostic impact on patients with basal carcinomas, Luminal B (except for RFS- HR 1.35, CI 95% 1.09–1.68, P = 0.0056, Fig. 3N) and HER2 + breast cancers. The gene discussed is ERBB2; the disease is breast carcinoma.